Kurin Inc., the inventor and manufacturer of 510(k)-cleared Kurin® blood culture collection sets, announced today that the Temple VA Hospital in Temple, TX, presented their findings comparing results of Kurin and Magnolia Medical’s Steripath at the recent Southwest Association of Clinical Microbiology. They are the first hospital to report on results comparing Kurin®, a passive low-volume diversion technology to Steripath®, a mechanical diversion device. They concluded that both products were effective. When they used Kurin, they had a blood culture contamination rate of 0.2%. The authors concluded that there was no difference in rates of specimen contamination, despite the fact that Kurin diverts significantly less blood than Steripath.
“We applaud the VA Temple for providing the first comparative study of these two products,” said Bob Rogers, Inventor and CEO of Kurin. “Although our clinical results from several hospitals have been similar to published results regarding Steripath, having both products tested by the same hospital offers a greater level of credibility to this conclusion.”
Kurin is the only diversion device with 510(k) clearance from the FDA and is the first device to allow for passive blood diversion, providing clinicians a seamless path to compliance. Outcomes are driven by compliance and compliance is a function of how simple technology is integrated into practice, which can be particularly challenging in the busy Emergency Department.
“Although it is not stated in the clinical publication, after the study concluded, the facility allowed the nurses to decide which product to use and we are pleased they chose Kurin,” said Mr. Rogers. “Our goal is to significantly improve patient outcomes while saving hospitals large sums of money and, given the importance of the Department of Veterans Affairs to our country, there is no group we are more pleased to assist than our veterans and those providing their care.”
About Kurin, Inc.
Kurin Corporation, a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.